JCR Pharmaceuticals Co., Ltd. announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo®?, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease. The achievement of a predefined research milestone triggers a milestone payment to JCR. JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
806 JPY | -0.86% | +1.64% | -31.23% |
Mar. 21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
Mar. 21 | JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.23% | 654M | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion